Harmony Biosciences Holdings Inc [HRMY] stock is trading at $34.43, up 2.26%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The HRMY shares have gain 6.99% over the last week, with a monthly amount drifted -11.22%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Harmony Biosciences Holdings Inc [NASDAQ: HRMY] stock has seen the most recent analyst activity on February 11, 2025, when Deutsche Bank initiated its Buy rating and assigned the stock a price target of $55. Previously, H.C. Wainwright started tracking the stock with Buy rating on December 17, 2024, and set its price target to $75. UBS started tracking the stock assigning a Buy rating and suggested a price target of $56 on September 10, 2024. Citigroup initiated its recommendation with a Buy and recommended $48 as its price target on June 21, 2024. BofA Securities downgraded its rating to Underperform for this stock on January 02, 2024, but kept the price target unchanged to $30. In a note dated September 25, 2023, Goldman downgraded an Sell rating on this stock and revised its target price from $40 to $31.
Harmony Biosciences Holdings Inc [HRMY] stock has fluctuated between $28.14 and $41.61 over the past year. Currently, Wall Street analysts expect the stock to reach $40 within the next 12 months. Harmony Biosciences Holdings Inc [NASDAQ: HRMY] shares were valued at $34.43 at the most recent close of the market. An investor can expect a potential return of 16.18% based on the average HRMY price forecast.
Analyzing the HRMY fundamentals
Harmony Biosciences Holdings Inc [NASDAQ:HRMY] reported sales of 714.73M for the trailing twelve months, which represents a growth of 19.51%. Gross Profit Margin for this corporation currently stands at 0.76% with Operating Profit Margin at 0.27%, Pretax Profit Margin comes in at 0.27%, and Net Profit Margin reading is 0.2%. To continue investigating profitability, this company’s Return on Assets is posted at 0.15, Equity is 0.25 and Total Capital is 0.23. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 33.40 points at the first support level, and at 32.38 for the second support level. However, for the 1st resistance point, the stock is sitting at 35.28, and for the 2nd resistance point, it is at 36.13.
Ratios To Look Out For
For context, Harmony Biosciences Holdings Inc’s Current Ratio is 3.31. Also, the Quick Ratio is 3.27, while the Cash Ratio stands at 2.59. Considering the valuation of this stock, the price to sales ratio is 2.76, the price to book ratio is 2.98 and price to earnings (TTM) ratio is 13.72.
Transactions by insiders
Recent insider trading involved Dierks Jeffrey, CHIEF COMMERCIAL OFFICER, that happened on Mar 03 ’25 when 4869.0 shares were sold. Officer, JEFFREY G DIERKS completed a deal on Mar 03 ’25 to buy 4869.0 shares. Meanwhile, CHIEF COMMERCIAL OFFICER Dierks Jeffrey sold 13125.0 shares on Jan 24 ’25.
